SomnoMed Limited’s shares are listed on the Australian Securities Exchange.

Annual Reports

2016 Annual Report
2015 Annual Report
2014 Annual Report
2013 Annual Report
2012 Annual Report
2011 Annual Report
2010 Annual Report

ASX Announcements – Q4 2017 (April 2017 – June 2017)

TDM Substantial Shareholder Notice SOM – 12.05.2017

ASX Announcements – Q3 2017 (January 2017 – March 2017)

Investor Presentation FY 16/17 Half Year Review 
Appendix 4D and Half-Year Financial Report December 2016
SOM Appendix 3B 1/3/17

ASX Announcements – Q2 2017 (October 2016 – December 2016)

Som Appendix 3B 19.12.16
Appendix 03YPN Dec 2016
TDM Substantial Shareholder Notice SOM – 08.12.2016
Somnomed Ltd [604 Change Filing Form] – 29.11.2016
AGM Results for ASX 2016
SomAppendix 3B 31.10.16
SomnoMed Appendix 4C Sept 2016 FINAL
Sales growth accelerating as Northern half returns from Summer holidays – September 2016 Release
SOM Wilsons October 2016
SomAppendix 3B7.10.16
SomnoMed Proxy 2016

Notice of AGM of SomnoMed 2016

ASX Announcements – Q1 2017 (July 2016 – September 2016)

Appendix 4G
FDA 510k approval for SomnoDent® Alpha
SomAppendix 3B1.9.16
TDM SSH 26.8.16
 – Form 604, Notice of change of interests of substantial holder
SomAppendix 3B 25.8.16
SOMApp3YPN 26.8.16
Form 605 Neustadt Shares 26.8.16
SomnoMed FY16 Presentation
SOM Preliminary Accounts FY16
Q4 ASX June 2016 Quarter Final
603 Initial Form SomnoMed Ltd – July 2016
SOM Appendix 4C – Quarterly Report for Entities Admitted on the Basis of Commitments 
Derek Smith appointed Global CEO of SomnoMed
CEO appointed for new direct to patient business entity

ASX Announcements – Q4 2016 (April 2016 – June 2016)

Wilson HTM Equity Research – SOM – 1 June 2016
Appendix 03Y Change of Director’s Interest Notice June 2016
Appendix 03Y PN Change of Director’s Interest Notice June 2016
Appendix 03Y LA Change of Director’s Interest Notice June 2016
Results of Retail entitlement offer: 1 June 16
Shareholding Info 6.6.2016
Form 604- Notice of change of interests of substantial holder 6 June 2016
SomnoMed – Appendix 3B – 6 June 2016
SomnoMed – Appendix 3B – 13 May 2016
Announcement of Dispatch of Entitlement Offer – May 2016
SomnoMed – Results of Institutional Offer – FINAL May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
Announcement of Entitlement Offer – May 2016

Cleansing Notice – May 2016
SOM Investors Presentation FINAL May 2016
SOM Chair Letter May 2016
SOM- Appendix 3B – May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
SOM Appendix 3B – April 2016

ASX Announcements – Q3 2016 (January 2016 – March 2016)

SomnoMed HY Accounts at 31 December 2015
SOM Investor Presentation February 2016
SOM Appendix 4C
Becoming a substantial holder

ASX Announcements – Q2 2016 (October 2015 – December 2015)

SomnoMed Ltd. acquires Strong Dental in Leamington, Ontario, Canada
SOM Appendix 3YLA
SOM Appendix 3YPN
SOM Appendix 3B
SomnoMed exceeds 250,000 patients
SomnoMed  Proxy 2015
Notice of AGM  of SomnoMed 2015
SOM Appendix 3B

ASX Announcements – Q1 2016 (July 2015 – September 2015)

SOM Appendix 4C
SomnoMed Appendix 4G September 2015
New Investor Form 603_090915
SomnoMed Appendix 3B_July 2015
SomnoMed Announcement – Strong Finish to Financial Year – July 2015

ASX Announcements – Q4 2015 (April 2015 – June 2015)

SomnoMed Appendix 4C June 2015 Quarter
Notice of Ceasing to be a Substantial holder_July 2015
FDA 510(k) Clearance letter for SomnoDent with compliance recorder
News Release:  SomnoMed receives FDA 510(k) approval for SomnoDent devices with wearable compliance micro-recording
News Release:  SomnoMed now offering SomnoDent with compliance recorder powered by DentiTrac
SomnoMed Update May 2015
Appendix 3B

ASX Announcements – Q3 2015 (January 2015 – March 2015)

Continuous Growth of SomnoMed in Third Quarter
Appendix 4C Quarterly (Q3)
Ceasing to be a substantial shareholder
Addition of SomnoMed to Australian All Ordinaries Index
Ceasing to be a substantial shareholder
Appendix 3B New issue announcement
Appendix 4D and Half-Year Financial Review
Investor Presentation: Financial Year 2014-2015 Half Year Review
SomnoMed Achieves Growth Targets
Appendix 3B New Issue Announcement January 2015
Appendix 4C Quarterly

ASX Announcements – Q2 2015 (October 2014 – December 2014)

Form 604 TDM Asset Management December 2014
Appendix 3B New Issue Announcement December 2014
Appendix 3YRS December 2014 – Change of Director’s Interest Notice
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3YPN – Change of Director’s Interest Notice
Appendix 3YRS – Change of Director’s Interest Notice
Form 604 Belgove December 2014
Appendix 3B New Issue Announcement: application for quotation of additional securities and agreement
Annual Meeting Minutes
SOM Shareholder Change Form Form 604
SomnoMed Exceeds 200,000 Patients
ASX Investor Presentation November 2014
SomnoMed Limited (SOM) Q1 Stock Analysis, Morgans CIMB
SomnoMed Limited (SOM) Q1 Stock Analysis, Wilson HTM
Notice of Annual General Meeting
SomnoMed Limited Proxy Form
Appendix 3B – New issue announcement,application for quotation of additional securities and agreement
New Records in September Confirm Guidance (ASX:SOM)
Appendix 4C – Quarterly report for entities admitted on the basis of commitments

ASX Announcements – Q1 2015 (July 2014 – September 2014)

US Medicare reimbursement approval granted for SOMNODENT® Herbst Advance
Appendix 3B New issue announcement
SomnoMed (“SOM”-ASX) Preliminary final report – 30 June 2014
SOM – Investor Presentation FY14
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3Y – Change of Director’s Interest Notice
SOM – Change in Substantial Holding
SomnoMed (“SOM”-ASX) Share Placement Update
SomnoMed SOM 708A Cleansing
SomnoMed Limited Appendix 3B – New Issue Announcement
SomnoMed (SOM) Research
SomnoMed Italy

Every State in the United States of America, and most countries throughout the world have their own laws regulating the types of securities and other investment products which maybe offered to their residents, as well as the process for doing so. As a result, investment in some securities is not available to every interested investor. Accordingly, this information is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell Somnomed Limited shares in any jurisdiction where such would be prohibited.

All investments involve different degrees of risk. In making any investment you should be aware of your risk tolerance level and financial situations at all times. Furthermore, you should seek professional investment advice before making any investment decisions. Somnomed Limited and/or its shareholders, directors, officers and/or employees make no investment recommendations in respect to any investment made in Somnomed Limited.